When was Nextbiotix founded?

Nextbiotix was founded in 2016 and raised its 1st funding round 2 years after it was founded.

Where is Nextbiotix located?

Nextbiotix is headquartered in Dijon, France.

How many employees does Nextbiotix have?

As of Jul 31, 2026, the latest employee count at Nextbiotix is 10.

Is Nextbiotix a funded company?

Nextbiotix is a funded company, having raised a total of $30.4M across 6 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Jul 05, 2018.

When was the latest funding round of Nextbiotix?

Nextbiotix's latest funding was a $***** Series A round on Oct 21, 2025, with participation from 4 investors.

Where does Nextbiotix rank among its competitors?

Nextbiotix ranks 31st amongst 375 active competitors, of which 130 are funded. It stands 10th in terms of total funding among its competitors. The most recent competitor to raise funding was Trimtech Therapeutics, which secured $14M in Jun, 2026.

Who are the top competitors of Nextbiotix?

Nextbiotix's top competitors include Novozymes, Upstream Bio and Odyssey. Among them, Trimtech Therapeutics secured the most recent funding round in June, 2026.

Nextbiotix - 2026 Company Profile, Team, Funding & Competitors

Company Details

Nextbiotix is developing microbiomes for the treatment of inflammatory bowel diseases. Its lead candidate, Live Biotherapeutics is a mono-strain of Faecalibacterium prausnitzii. It is being developed for Crohn's disease and ulcerative colitis. The bacteria shows anti-inflammatory effects and modulates immune activity in the gut. The company is in the preclinical stage.

Key Metrics

Founded Year

2016

Location

Dijon, France

Stage

Series A

Total Funding

$30.4M in 6 rounds

Latest Funding Round

Series A, Oct 21, 2025, $*****

Investors

Auriga Partners & 11 more

Ranked

31^st among 375 active competitors

Employee Count

10 as on Jul 31, 2026

Similar Companies

Novozymes & 457 more

View Nextbiotix's full profile

Nextbiotix has raised a total funding of $30.4M over 6 rounds. Its first funding round was on Jul 05, 2018. Its latest funding round was a Series A round on Oct 21, 2025 for $*****. 4 investors participated in its latest round. Nextbiotix has 12 institutional investors.

Here is the list of recent funding rounds of Nextbiotix:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Oct 21, 2025	2887090	Series A	8990859	2570961	4117100	8848429
Jul 03, 2023	7397825	Series A	1263915	9243548	9734098	Biocodex & 1 more
Mar 31, 2023	6514592	Grant (prize money)	4567619	5859471	2049269	EIC Fund

Access funding benchmarks and valuations. Sign up today!

View details of Nextbiotix's funding rounds and investors

The founders of Nextbiotix are Harry Sokol and Patrick Gervais.

Here are the details of Nextbiotix's key team members:

Harry Sokol: Co-Founder of Nextbiotix.
Patrick Gervais: Co-Founder of Nextbiotix.

View details of Nextbiotix's Founder profiles and Board Members

Nextbiotix's employee count trend

Nextbiotix has 10 employees as of Jul 26. Here is Nextbiotix's employee count trend over the years:

Uncover Nextbiotix's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Nextbiotix include Novozymes, Upstream Bio and Odyssey. Here is the list of Top 10 competitors of Nextbiotix, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Novozymes 2000, Bagsvaerd (Denmark), Acquired	Developer of biosolutions and enzymes for multiple industries and applications of biotechnology	$9.75M	DOE, OSTI & 3 others	73/100
2nd	Upstream Bio 2021, Waltham (United States), Public	Developer of therapeutics for allergic and inflammatory diseases	$400M	Venrock, Orbimed & 11 others	67/100
3rd	Odyssey 2018, Cambridge (United States), Public	Developer of immunotherapeutics for immunological and cancer diseases	$717M	Orbimed, Ascenta Capital & 29 others	66/100
4th	Septerna 2020, San Bruno (United States), Public	Developer of GPCR drug discovery platform for multiple diseases	$250M	RA Capital Management, Third Rock Ventures ... & 14 others	66/100
5th	Ventyx Biosciences 2018, Encinitas (United States), Acquired	Developer of therapeutics to treat autoimmune diseases	$165M	VenBio, Logos Capital & 13 others	66/100
6th	Evommune 2020, Sacramento (United States), Public	Developer of therapeutic options for chronic inflammatory disorders	$276M	Pivotal bioVenture Partners, SymBiosis & 18 others	66/100
7th	CalciMedica 2006, San Diego (United States), Public	Developer of CRAC channel inhibitor drugs for inflammatory diseases	$76.7M	Biogen, Valence Life Sciences & 11 others	64/100
8th	Inotrem 2013, Paris (France), Series B	Developer of peptide immunotherapies for treating septic shock and acute myocardial infarction	$122M	Morningside, Morningside & 11 others	62/100
9th	Trimtech Therapeutics 2023, Cambridge (United Kingdom), Seed	They develop treatments for CNS and inflammatory disorders	$47M	Cambridge Innovation Capital, SV Health Investors ... & 11 others	61/100
10th	Seres Therapeutics 2010, Cambridge (United States), Public	Developer of microbiome therapeutics to treat a wide range of diseases	$134M	Flagship Pioneering, Mayo Clinic Business Accelerator ... & 8 others	60/100
31st	Nextbiotix 2016, Dijon (France), Series A	Developer of probiotic for the treatment of inflammatory bowel diseases	$30.4M	Crescent Enterprises, Auriga Partners & 10 others	54/100